Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant Rejection.

Background: Alemtuzumab can be an alternative to rabbit anti-thymocyte globulin (rATG) to treat severe or glucocorticoid-resistant acute T cell-mediated kidney transplant rejection (TCMR). Yet, there are few reports in which these two treatments are evaluated let alone, compared. This study describes the real-world clinical experience of both therapies and compares their efficacy and toxicity.

Heart disease detection using an acceleration-deceleration curve-based neural network with consumer-grade smartwatch data.

Cardiovascular disease (CVD) is the most important cause of morbidity and mortality worldwide. Early detection, prevention or even prediction is of pivotal importance to reduce the burden of cardiovascular disease and its associated costs. Low cost, consumer-grade smartwatches have the potential to revolutionize cardiovascular medicine by enabling continuous monitoring of heart rate and activity.

Holmium-166 radioembolisation dosimetry in HCC.

Purpose: To evaluate dosimetry, dose-response and dose-toxicity relationships for holmium-166 (Ho) radioembolisation in patients with hepatocellular carcinoma (HCC).

Methods: Thirty-one patients with hepatocellular carcinoma were included in the HEPAR Primary study (NCT03379844, registered on December 20th, 2017) and underwent Ho-microspheres radioembolisation. Linear mixed models assessed the association between tumour absorbed doses and response based on mRECIST both on tumour and patient level.